Superior MSRE-Free & Bisulfite-Free DNA Methylation Analysis close
  • Making more of specific proteins helps cancer cells survive under conditions which would kill normal cells. All these cells are being starved. The large cells have been genetically modified to over-express SMAC/DIABLO (green), one protein involved in apoptosis. The normal cells are stressed and form red stress granules. Understanding how cancer cells subvert the death pathway may lead to new ways to treat cancer. Immunofluorescent photomicrograph. --- Image by © Nancy Kedersha/Science Faction/Corbis

Leading the way in DNA Methylation Diagnostic and Research Solutions

Research Products & Services

RiboMed provides bisulfite-free and MSRE-free products and services for the ultra-sensitive & quantitative measurement of DNA methylation, even in FFPE tissues and bodily fluids used for liquid biopsies.

MethylMagnet®: Separation of Methylated & Unmethylated DNA based on DNA methylation density

MethylMeter® – A new standard for sensitivity in quantitative DNA methylation measurements with small quantities of DNA

read more

imgres

Clinical Diagnostics

RiboMed’s tests are offered in the CLIA certified/CAP accredited Ribomed Clinical Services Lab.

GliomaSTRAT measures genetic and epigenetic markers involved in brain cancer (glioma, GBM) and includes
(1) MGMT methylation measurement to predict TMZ response and

(2) glioma subtype determination with G-CIMP (glioma CpG island methylator phenotype) assignment and IDH1 WT and R132H mutation analysis.

Both multi-gene DNA methylation and mutational analysis in one assay with nanograms of DNA.

Physicians & Clinical Trial Customers:
To order the GliomaSTRAT test or any of its component parts (MGMT, IDH1 WT/R132H, G-CIMP) for analysis in Ribomed’s CLIA laboratory, contact Ribomed Clinical Services Lab.  ribomedcsl@ribomed.com.

GliomaSTRAT: Glioma Stratification for subtyping & drug response prediction

read more

Latest News

RiboMed CEO to speak at 5th Cancer Epigenetics Conference in San Francisco Nov 9, part of the Novel Cancer Therapeutics Summit.

Ribomed and Tocagen collaborate to analyze epigenetic prognostic markers including MGMT in recurrent brain tumors

Study Published in Science Translational Medicine reports favorable Safety and Extended Survival for Brain cancer Patients Treated with Tocagen’s Cancer-Selective Viral Gene Therapy

read more

© Copyright - Ribomed - Wordpress Theme by Kriesi.at